Skip to main content

Advertisement

Table 1 Baseline characteristics of enrolled patients.

From: Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial

Characteristic Treatment arm
Number of patients randomized CQ (n = 268) DP (n = 268) P
Gender: Male/Female (ratio) 126/142 (0.89) 132/136 (0.97) 0.60
Age, median years (range) 11 (0.25 -71) 12 (1 - 70) 0.38
Age Groups:    0.18
   <5 years 43 (16.0) 30 (11.2)  
   5 -14 years 130 (48.5) 128 (47.8)  
   >14 years 95 (35.5) 110 (41.0)  
Location:    0.61
   Jalalabad 154 (57.5) 160 (59.7)  
   Taloqan 58 (21.6) 61 (22.8)  
   Maimana 56 (20.9) 47 (17.5)  
Weight, median kg (range) 30 (5-93) 33 (7-89) 0.69
Geometric mean parasitaemia/μL (95% CI) 3339 (3000-3716) 3236 (2940 -3560) 0.67
Number with gametocytes 218 (81.3) 203 (75.2) 0.12
Haemoglobin concentration, mean g/dl (SD) 10.9 (1.46) 10.9 (1.42) 0.99
Anaemia (haemoglobin concentration < 10 g/dl) 49 (18.4) 44 (16.5) 0.35
Median white blood cells ×109/ml, median (range) 6.0 (3.6-54) 6.6 (3.0-12.4) 0.02
Body temperature °C, mean (95% CI) 37.3 (37.2-37.4) 37.3 (37.2-37.4) 0.77
Median systolic blood pressure, mmHg (range) 100 (80-160) 100 (80-170) 0.43
Median diastolic blood pressure, mmHg (range) 70 (50-100) 70 (50-100) 0.38
Median pulse rate, beat/min (range) 88 (60-140) 88 (60-140) 0.53
Jaundice 30 (11.3) 32 (12.1) 0.79
History of convulsions in last 24 hours 1 (0.37) 1 (0.37)  
  1. Data for chloroquine (CQ) and dihydroartemisinin-piperaquine (DP) are number (%) unless otherwise indicated.